NSCLC

[Molecular Therapy] Scientists investigated the interconnected pathways underlying the promotion of cisplatin-induced metastases.

[Clinical Cancer Research] Researchers investigated sex-based differences in the molecular mechanisms of anticancer immune-response and immune evasion in patients with non-small cell lung cancer.

[Novocure, Inc. (Business Wire, Inc.)] Novocure, Inc. announced the US FDA has approved the company’s Investigational Device Exemption supplement, reducing the enrollment requirement for its LUNAR trial to 276 patients with 12 months follow-up. LUNAR is a phase 3 pivotal trial testing the effectiveness of Tumor Treating Fields in combination with immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone for patients with stage IV NSCLC who progressed during or after platinum-based therapy.

[Science Advances] REsearchers developed a previously unidentified index, the T cell receptor (TCR)-based immunotherapy response index (TIR index), that estimated the degree of overlap of the TCR repertoire between tumor-infiltrating lymphocytes and circulating PD-1+CD8+T cells

[Nature Cancer] Investigators found that LKB1 deficiency correlated with elevated tumor mutational burden (TMB) in nonsmall cell lung cancers from nonsmokers and genetically engineered mouse models, despite the frequent association between high-TMB and anti-PD-1 treatment efficacy.

[Molecular Therapy-Oncolytics] Researchers discuss the technologies for detection and enrichment of circulating tumor cells, as well as clinical applications involving circulating tumor cells.